GSK-3 Inhibitor II,
GSK-3beta Inhibitor II,
478482-75-6,
2-Thio(3-iodobenzyl)-5-(1-pyridyl)-[1,3,4]-oxadiazole,
Glycogen Synthase Kinase-3beta Inhibitor II,
Pyridine,4-[5-[[(3-iodophenyl)methyl]thio]-1,3,4-oxadiazol-2-yl]-,
K00026,
AC1O702O,
BDBM8552,
CHEMBL288064,
GTPL5978,
SCHEMBL5022122,
CHEBI:91342,
CTK8E9270,
DTXSID10424894,
HMS3229G14,
HMS3265E17,
HMS3265E18,
HMS3265F17,
HMS3265F18,
HSCI1_000107,
IN1318,
ZINC13442468,
CCG-206842,
oxadiazole-pyridyl containing compound 12,
RT-013124,
BRD-K09991945-001-01-2,
2-(3-Iodobenzylthio)-5-(4-pyridyl)-1,3,4-oxadiazole,
2-[(3-iodophenyl)methylsulfanyl]-5-pyridin-4-yl-1,3,4-oxadiazole,
2-{[(3-iodophenyl)methyl]sulfanyl}-5-(pyridin-4-yl)-1,3,4-oxadiazole,
4-(5-{[(3-iodophenyl)methyl]sulfanyl}-1,3,4-oxadiazol-2-yl)pyridine,
GSK-3b inhibitor II,
D01MEP,
CID6539732,
Pyridine, 4-[5-[[(3-iodophenyl)methyl]thio]-1,3,4-oxadiazol-2-yl]-,